Loading
Loading
Hormonal & Fertility Support · 10mg
Janoshik-tested · 10 vials per kit
PT-141 (Bremelanotide) is a cyclic peptide melanocortin receptor agonist derived from alpha-MSH, studied in preclinical and clinical research for its role in sexual function. Research has examined its potential to act on central MC3R/MC4R pathways, improve erectile function through corpus cavernosum smooth muscle relaxation, and enhance sexual desire via CNS-mediated libido regulation. Its mechanism is distinct from PDE5-inhibitor pathways, with rapid onset demonstrated in evaluations.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
PT-141
Bremelanotide
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide related to Melanotan II, differing at the C-terminus. It was identified serendipitously during MT-2 human trials when researchers noted sexual arousal as a prominent effect. Approved by the FDA in 2019 as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Unlike PDE5 inhibitors (sildenafil, tadalafil) which act peripherally through vascular smooth muscle relaxation, PT-141 acts centrally via melanocortin MC4R in the hypothalamus and limbic system, activating dopaminergic pathways associated with sexual motivation, desire, and arousal. This central mechanism means it can activate sexual response in the absence of physical stimulation and works through the same neural pathway in both men and women.
Clinical trials demonstrated improvement in sexually satisfying events and desire scores in premenopausal women with HSDD. Studies in male sexual dysfunction showed dose-dependent improvement in erectile response. Unlike MT-2, PT-141's reduced MC1R activity means it produces minimal melanogenesis at therapeutic doses. Key side effects in trials included transient nausea, flushing, and blood pressure elevation.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
